Khandker, Rezaul Karim
Chekani, Farid
Mirchandani, Kirti
Kathe, Niranjan
Article History
Received: 3 October 2022
Accepted: 30 January 2023
First Online: 17 February 2023
Declarations
:
: All the methods in this research study were carried out in accordance with the Declaration of Helsinki. This study was exempt from review by an institutional review board (as defined at 45 CFR 46.102(f)(2)) because IBM® provided de-identified data from the IBM® MarketScan® Commercial Claims and Encounters and Medicare Supplemental Databases, fully compliant with U.S. privacy laws and regulations, that is, the Health Insurance Portability and Accountability Act (HIPAA). Administrative permissions were obtained from IBM® Watson HealthTM to access the de-identified data used in this study.
: Not applicable.
: Farid Chekani and Rezaul Karim Khandker are employees of Merck Sharp & Dohme Corp., a Merck & Co., Inc. subsidiary, Kenilworth, NJ, USA, who may own and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. Kirti Mirchandani is an employee of Complete HEOR Solutions, North Wales, PA, USA, which received financial compensation to conduct the study analysis. Niranjan Kathe was an employee of Complete HEOR Solutions when the study was conducted. The authors report no other relevant conflicts of interest to report.